KYNB · XBRL financial data

Kyntra Bio financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KYNB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue	176	235	141	148	30	6
Revenue from contracts with customers	176	235	141	148	30	6
Cost of revenue	9	13	20	19	16	1
Research and development	253	387	297	283	96	24
Selling, general and administrative	106	124	125	115	49	28
Total operating expenses	368	—	—	—	—	—
Operating income (loss)	(192)	(289)	(301)	(282)	(150)	(46)
Interest expense	2	1	1	16	8	9
Income tax expense (benefit)	0	0	0	0	(0)	(0)
Net income (loss)	(189)	(290)	(294)	(284)	(48)	183
Earnings per share, basic USD per share	(2.11)	(3.14)	(3.14)	(2.92)	(0.48)	45.37
Earnings per share, diluted USD per share	(2.11)	(3.14)	(3.14)	(2.92)	(0.48)	45.37
Weighted average shares, basic millions of shares	90	92	94	97	100	4
Weighted average shares, diluted millions of shares	90	92	94	97	100	4

† Share count changed about 1/25 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KYNB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	678	171	156	114	50	48
Short-term investments	8	234	266	122	0	41
Accounts receivable	42	17	16	13	0	0
Inventory	17	31	40	42	3	4
Prepaid and other current assets	10	20	14	42	32	6
Total current assets	755	474	493	332	197	99
Property and equipment, net	34	28	21	13	0	—
Right-of-use asset	2	91	80	68	0	—
Total assets	827	774	610	424	215	120
Accounts payable	25	26	31	18	5	4
Accrued liabilities	120	173	220	173	62	20
Total current liabilities	163	225	274	218	133	29
Lease liability, non-current	1	89	80	67	0	—
Total liabilities	385	545	612	586	398	115
Accumulated deficit	(974)	(1,264)	(1,558)	(1,842)	(1,889)	(1,706)
Total stockholders' equity	422	209	(21)	(204)	(226)	(30)
Total liabilities and equity	827	774	610	424	215	120
Common shares outstanding (cover page) millions of shares	92	93	94	99	101	4

† Share count changed about 1/25 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KYNB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(189)	(290)	(294)	(284)	(48)	183
Stock-based compensation	73	71	66	51	25	7
Net cash from operating activities	82	(82)	(146)	(315)	(138)	(5)
Purchases of property and equipment	4	5	4	3	0	0
Net cash from investing activities	452	(427)	89	154	126	35
Proceeds from issuing common stock	38	13	4	4	0	0
Net cash from financing activities	13	(1)	47	123	(0)	(86)
Net change in cash	552	(507)	(16)	(42)	(12)	(54)

† Share count changed about 1/25 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Fibrogen	51	(1.5)	(4)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	24	not reported	(8.7)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Imunon	6.9	not reported	(3)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1.7	0*	(1.8)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Dare Bioscience	13	0.2	(6.8)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1	not reported	(5.8)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Ovid Therapeutics	11	0.7	(18)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
vTv Therapeutics	87	0	(11)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8.4	42	2.2*	403.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.